Retrospective evaluation of non-small cell lung cancer patients in Kırıkkale
Kırıkkale ilinde küçük hücre dışı akciğer kanseri tanılı hastaların retrospektif değerlendirilmesi
Murat Doğan 1, Selim Yalçın 2 * , Şeyma Üneşi 1
1 Kırıkkale Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Kırıkkale, Türkiye
2 Kırıkkale Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Tıbbi Onkoloji Bilim Dalı. Kırıkkale, Türkiye
* Corresponding Author
Ortadogu Tıp Derg, Volume 10, Issue 2, pp. 103-109
https://doi.org/10.21601/ortadogutipdergisi.335600
OPEN ACCESS
Download Full Text (PDF)
Abstract
Aim: In this study, we aimed to determine the clinical and epidemiological features of lung cancer patients, treatment modalities, survival and factors affecting survival in the patients who were followed up at our clinic retrospectively.
Material and Method: Ninety two non-small cell lung cancer patients who were referred to Kirikkale Faculty of Medicine, Departmant of Medical Oncology Clinic between January 2012-May 2016 were included in the study.
Results: 81 patients were male (88%) and 11 females (12%),that mean age was 65,3±8,99 years. 86.6% of the patients are actively smokers. At the time of diagnosis 94.5% of patients were ECOG 0-1 performance status. For histopathologic subgroups, 47 (51.1%) adenocarsinomo, 39 (42.4%) were squuamouscell carcinoma, 6 (6.5%) other NSCLC subtypes. The presence of lymphovascular invasion is compared with tumor types, lymphovascular invasion have observed in 62.5% (n=5) of adenocarcinoma, 37.5% (n=3) of squamous cell carcinoma. In the 29.6% (n=8) of the cases, there was lymphovascular invasion but the lymphovascular invasion have not observed in the majority of the patients (%70.4, n=19). Median survival was 23.4 months in males, 18.1 months in women (p= 0.63). The survival was effected by lymphovascular invasion, ECOG performance status and cancer stage but not by age, sex, co-morbidity, smoking, cancer type, treating with chemotherapy, existing brain metastasis.
Conclusions: In conclusion, our study evaluates clinical, histologic, survival features and factors affecting survival in non-small cell lung cancer patients who were followed up at our clinic.
Öz
Amaç: Bu çalışmada kliniğimizde izlenen küçük hücre dışı akciğer kanseri (KHDAK) hastalarının klinik ve epidemiyolojik özellikleri, tedavileri, ortalama sağ kalımı, sağ kalımı etkileyen faktörleri saptamayı amaçladık.
Gereç ve Yöntem: Retrospektif dizayndaki bu çalışmaya Kırıkkale Tıp Fakültesi İç Hastalıkları Anabilim Dalı Tıbbi Onkoloji polikliniğine Ocak 2012-Mayıs 2016 tarihleri arasında tanı ve tedavi amacıyla başvuran 92 küçük hücre dışı akciğer kanseri hastası dahil edildi.
Bulgular: Hastaların 81’i erkek (%88), 11’i kadın (%12), yaş ortalaması 65.3±8.99 idi (min:41, max:94). Olguların %86,6 ’i aktif sigara içicisiydi. Hastaların %94,5’inin başvuru sırasında ECOG performans durumları 0 veya 1’di. Histolojik alt gruplara göre hastaların 47 (%51,1)’i adenokarsinom, 39 (%42,4)’ü skuamöz hücreli karsinom ve 6 (%6,5)’u diğer KHDAK’idi. Tümör tipleri ile lenfovasküler invazyon varlığı karşılaştırıldığında adenokarsinomların %62,5’inde (n=5), squamöz hücreli karsinomların %37,5’inde (n=3) lenfovasküler invazyonun olduğu görülmüştür. Olguların %29,6’sında (n=8) lenfovasküler invazyon varken %70,4’ünde (n=19) olmadığı görüldü. Lenfovasküler invazyon, ECOG performans durumu ve kanser evresi sağ kalım üzerinde etkili bulunurken, yaş, cinsiyet, komorbiditeler, sigara kullanımı, kanser tipi, kemoterapi ve beyin metastazları sağ kalım üzerinde etkili değildi. Erkekler için ortanca sağ kalım 23,4 ay, kadınlar için ise 18,1 aydı (p:0.633).
Sonuç: Çalışmamızda kliniğimizde takip edilen küçük hücre dışı akciğer kanseri hastalarının klinik, histolojik, sağ kalım özellikleri ve sağ kalım üzerinde etkili olan faktörler değerlendirilmiştir.
- Spiro SG, Porter JC Lung cancer – Where are we today? Current
advances in staging and nonsurgical treatment. Am J Respir Crit
Care Med 166: 1166–1196,2002.
- Jemal A, Bray F et al. “Global cancer statistics.” CA Cancer J Clin
61: 69-90,2011.
- Nacht M, Dracheva T, Gao Y, et al. Molecular characteristics of nonsmall cell lung cancer. ProcNatl Acad Sci U S A. 2001; 98: 15203-8.
- Novaes FT, Cataneo DC. Lung cancer: histology, staging, treatment
and survival. J Bras Pneumol 2008; 34: 595-600.
- Cappuzzo F, Ligorio C, Toschi L, et al. EGFR and HER2 gene
copy number and response to first-line chemotherapy in patients
with advanced non-small cell lung cancer (NSCLC). J Thorac
Oncol 2007; 2: 423-9.
- Tu H, Heymach JV, Wen C-P, et al. Different dietary patterns and
reduction of lung cancer risk: A large case-control study in the
U.S. Scientific Reports 2016;6:26760. doi:10.1038/srep26760.
- Chen J, Li W, Cui L, et al. Chemotherapeutic Response and Prognosis
among Lung Cancer Patients with and without Depression. Journal
of Cancer. 2015;6: 1121-1129. doi:10.7150/jca.11239.
- Yin J, Li Y, Zhao H, et al. Copy‐number variation of MCL1
predicts overall survival of non‐small‐cell lung cancer in a
Southern Chinese population. Cancer Medicine May 2016:10.1002/
cam4.774. doi:10.1002/cam4.774.
- Lis CG, Patel K, Gupta D. The Relationship between Patient
Satisfaction with Service Quality and Survival in Non-Small Cell
Lung Cancer – Is Self-Rated Health a Potential Confounder? de
Mello RA, ed. PLoS ONE. 2015;10:e0134617.
- Chaari A, Ben Nasr S, Labidi S, Afrit M, Boussen H. Metastatic
non-small cell lung cancer: a Tunisian retrospective study about
100 cases. Tunis Med. 2015 May;93:294-6.
- Eichler AF, Chung E, Kodack DP, Loeffler JS, Fukumura D, Jain
RK. The biology of brain metastases-translation to new therapies.
Nat Rev Clin Oncol 2011;8:344–56. Epub 2011/04/14.
- Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, et
al. Survival and neurologic outcomes in a randomized trial of
motexafin gadolinium and whole-brain radiation therapy in brain
metastases. J Clin Oncol. 2003;21:2529–36. Epub 2003/06/28.
- Tigin C, Kıyık M, Çıkrıkçıoğlu S, et al. The role of computed
tomography in the detection of brain metastasis in non-small cell
lung cancer. Medical bulletin of Heybeliada 2003; 9:16-8.
- Li BT, Lou E, Hsu M, et al. Serum Biomarkers Associated with
Clinical Outcomes Fail to Predict Brain Metastases in Patients
with Stage IV Non-Small Cell Lung Cancers. Dutt A, ed. PLoS
ONE. 2016;11:e0146063. doi:10.1371/journal.pone.0146063.
- Özgül A,Uysal A, Kadakal F,Altoparlak B, Cinemre H, Yılmaz
V. Küçük hücreli dışı akciğer kanseri beyin metastazı tanısında
bilgisayarlı beyin tomografisi ve manyetik rezonans görüntüleme
yönteminin karşılaştırılması. Tüberküloz ve Toraks Derg 2006,54.
- Wisnivesky JP, Yankelevitz D, Henschke CI. Stage of lung cancer
in relation to its size: part 2. Evidence. Chest 2005;127:1136–1139.
- Nakayama H, Satoh H, Kurishima K, Ishikawa H. Tokuuye K.
High-dose conformal radiotherapy for patients with stage III
non-small-cell lung carcinoma. Int. J. Radiat Oncol Biol Phys
2010;78:645–50.
- Rades D, Setter C, Dahl O, Schild SE. Noack F. Prognostic impact
of erythropoietin expression and erythropoietin receptor expression
on locoregional control and survival of patients irradiated for stage
II/III non-small-cell lung cancer. Int. J. Radiat Oncol Biol Phys
2011;80:499–505.
- Shen G, Bian G, Yu H, Gao M, Kang D, Hu S. Comparison between
cisplatin plus vinorelbine and cisplatin plus docetaxel in the
treatment of advanced non-small-cell lung cancer: A meta-analysis
of randomized controlled trials. Mol Clin Oncol 2014;2:146–50.
- Owonikoko TK, Ragin C, Chen Z, Kim S, Behera M, Brandes JC, Saba
NF, Pentz R, Ramalingam SS, Khuri FR. Real-world effectiveness of
systemic agents approved for advanced nonsmall cell lung cancer: a
SEER-Medicare analysis. Oncologist 2013;18:600–610.
- Shen G, Bian G, Yu H, Gao M, Kang D, Hu S. Comparison between
cisplatin plus vinorelbine and cisplatin plus docetaxel in the
treatment of advanced non-small-cell lung cancer: A meta-analysis
of randomized controlled trials. Mol Clin Oncol 2014;2:146–50.
- Ahn MJ, Lee J, Park YH et al. Korean ethnicity as compared with
white ethnicity is an independent favorable prognostic factor for
overall survival in non-small cell lung cancer before and after the
oral epidermal growth factor receptor tyrosine. kinase inhibitor
era. J Thorac Oncol 2010;5:1185–96.
Citation